SCHEMBL19995259

SCHEMBL19995259

Oc1nc(-c2ccnc(F)c2)nc(Cl)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 1/20 0.40
▸ ADORA2B P29275 6/20 0.39
▸ ADORA2A P29274 3/20 0.39
▸ MAP4K4 O95819 3/20 0.36
▸ MINK1 Q8N4C8 3/20 0.36
▸ TNIK Q9UKE5 3/20 0.36
▸ S1PR1 P21453 1/20 0.36
▸ MAPK1 P28482 1/20 0.35
▸ NQO2 P16083 2/20 0.35
▸ CAPN1 P07384 1/20 0.35
▸ PRKCI P41743 1/20 0.34
▸ SYK P43405 1/20 0.33
▸ MAPK13 O15264 1/20 0.33
▸ MAPK12 P53778 1/20 0.33
▸ MAPK11 Q15759 1/20 0.33
▸ MAPK14 Q16539 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ NFATC1 O95644 1/20 0.32
▸ DYRK1A Q13627 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30062972 1.00 IDO1 (0.40) IDO1ADORA2BADORA2AMAP4K4MINK1
SCHEMBL30060976 0.89 IDO1 (0.45) IDO1ADORA2BADORA2AMAP4K4MINK1
SCHEMBL19995233 0.89 IDO1 (0.45) IDO1ADORA2BADORA2AMAP4K4MINK1
SCHEMBL30062513 0.82 IDO1 (0.45) IDO1ADORA2BADORA2AMAP4K4MINK1
SCHEMBL20012012 0.82 IDO1 (0.45) IDO1ADORA2BADORA2AMAP4K4MINK1
SCHEMBL26030813 0.77 IDO1 (0.53) IDO1ADORA2BADORA2AMAP4K4MINK1
SCHEMBL22563204 0.71 MAPK13 (0.38) IDO1ADORA2BADORA2AMAPK1MAPK13
SCHEMBL22068158 0.69 IDO1 (0.55) IDO1ADORA2BADORA2AMAP4K4MINK1
SCHEMBL30298973 0.68 IDO1 (0.52) IDO1ADORA2BADORA2AMAP4K4MINK1
SCHEMBL20012426 0.68 MAPK14 (0.40) IDO1ADORA2BADORA2AMAP4K4MINK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110036006-B Preparation and use of pyrimidinone derivatives 癌症研究科技有限公司 2022-12-13 — — CN disclosed
US-10919896-B2 Preparation and uses of pyrimidinone derivatives CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-02-16 — — US disclosed
EP-3515903-B1 PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES CANCER RESEARCH TECH LTD (GB) 2020-10-21 — — EP disclosed
US-20200123157-A1 PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. 2020-04-23 — — US disclosed
EP-3515903-A1 PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES Cancer Research Technology Limited (GB) 2019-07-31 — — EP disclosed
WO-2018055402-A1 PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-03-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10919896-B2 Preparation and uses of pyrimidinone derivatives CDC7, CDK7, CDK17 IDO1 2515/4885ADORA2B 3813/4885ADORA2A 3107/4885
US-20200123157-A1 PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE CDC7, CDK7, CDK17 IDO1 2686/4885ADORA2B 3896/4885ADORA2A 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback